Cancer Cell Plasticity

Research group

Ketola group

Cancer Cell Plasticity, Cancer Neuroscience

Current treatment options for prostate cancer include use of androgen deprivation therapies to block tumor growth but often, the tumors become castration-resistant. Even the second generation antiandrogens that do have significant effect on castration-resistant tumor growth in patients are not curative. Approximately 25% of prostate cancer patients with castration-resistant disease treated with antiandrogens develop a form of prostate cancer that is completely independent of androgen receptor signaling that fuels the tumor growth. Analyses of the pathology and genomics of these patient tumors has identified that the tumor cells adapt cancer stem cell and neuronal cell characteristics. Currently, there are no targeted treatment options for this patient group. Thus, development of novel strategies including selection of drugs that could be used to reduce the tumor growth and metastases in this patient group are desperately needed. We study the molecular mechanisms of cellular plasticity and treatment resistance and aim at characterizing novel therapeutic targets and targeted therapies against aggressive, treatment resistant prostate cancer subtypes including treatment-induced neuroendocrine prostate cancer.
Homepage of the group


Group members - UEF

Other group members

  • Roosa Kaarijärvi
    Roosa Kaarijärvi
  • Noora Laulumaa
    Noora Laulumaa
  • Tomas Darth
    Tomas Darth
  • Emmi Järvelä
    Emmi Järvelä
  • Maruf Sahariar
    Maruf Sahariar
  • Eerika Takala
    Eerika Takala
  • Okko Kääriäinen
    Okko Kääriäinen
  • Kirsi Kainulainen
    Kirsi Kainulainen
  • Merja Räsänen
    Merja Räsänen
  • Henna Tynjälä
    Henna Tynjälä

Cooperation partners